Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.70), $0.01 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $5.6 million versus the consensus estimate of $6.32 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.